APH Stock Overview
Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally.
Alliance Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£1.02|
|52 Week High||UK£1.23|
|52 Week Low||UK£0.72|
|1 Month Change||-0.97%|
|3 Month Change||-5.74%|
|1 Year Change||38.32%|
|3 Year Change||49.71%|
|5 Year Change||128.76%|
|Change since IPO||409.00%|
Recent News & Updates
An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued
Today we will run through one way of estimating the intrinsic value of Alliance Pharma plc ( LON:APH ) by taking the...
Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
|APH||GB Pharmaceuticals||GB Market|
Return vs Industry: APH exceeded the UK Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: APH exceeded the UK Market which returned 13.8% over the past year.
|APH Average Weekly Movement||3.0%|
|Pharmaceuticals Industry Average Movement||5.7%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.8%|
|10% least volatile stocks in GB Market||2.5%|
Stable Share Price: APH is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: APH's weekly volatility (3%) has been stable over the past year.
About the Company
Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It owns or licenses the rights to approximately 80 pharmaceutical and consumer healthcare products.
Alliance Pharma Fundamentals Summary
|APH fundamental statistics|
Is APH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|APH income statement (TTM)|
|Cost of Revenue||UK£50.90m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.034|
|Net Profit Margin||12.29%|
How did APH perform over the long term?See historical performance and comparison
1.6%Current Dividend Yield
Does APH pay a reliable dividends?See APH dividend history and benchmarks
|Alliance Pharma dividend dates|
|Ex Dividend Date||Dec 16 2021|
|Dividend Pay Date||Jan 07 2022|
|Days until Ex dividend||15 days|
|Days until Dividend pay date||37 days|
Does APH pay a reliable dividends?See APH dividend history and benchmarks
Is Alliance Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: APH (£1.02) is trading below our estimate of fair value (£2.13)
Significantly Below Fair Value: APH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: APH is poor value based on its PE Ratio (30.3x) compared to the UK Pharmaceuticals industry average (29.7x).
PE vs Market: APH is poor value based on its PE Ratio (30.3x) compared to the UK market (19x).
Price to Earnings Growth Ratio
PEG Ratio: APH is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: APH is good value based on its PB Ratio (2x) compared to the GB Pharmaceuticals industry average (4.5x).
How is Alliance Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APH's forecast earnings growth (15.7% per year) is above the savings rate (0.9%).
Earnings vs Market: APH's earnings (15.7% per year) are forecast to grow faster than the UK market (12.6% per year).
High Growth Earnings: APH's earnings are forecast to grow, but not significantly.
Revenue vs Market: APH's revenue (9.6% per year) is forecast to grow faster than the UK market (4.9% per year).
High Growth Revenue: APH's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APH's Return on Equity is forecast to be low in 3 years time (10.9%).
How has Alliance Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APH has high quality earnings.
Growing Profit Margin: APH's current net profit margins (12.3%) are higher than last year (8.5%).
Past Earnings Growth Analysis
Earnings Trend: APH's earnings have declined by 8.9% per year over the past 5 years.
Accelerating Growth: APH's earnings growth over the past year (62.5%) exceeds its 5-year average (-8.9% per year).
Earnings vs Industry: APH earnings growth over the past year (62.5%) exceeded the Pharmaceuticals industry -20.6%.
Return on Equity
High ROE: APH's Return on Equity (6.4%) is considered low.
How is Alliance Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: APH's short term assets (£84.8M) exceed its short term liabilities (£38.5M).
Long Term Liabilities: APH's short term assets (£84.8M) do not cover its long term liabilities (£195.3M).
Debt to Equity History and Analysis
Debt Level: APH's net debt to equity ratio (37.6%) is considered satisfactory.
Reducing Debt: APH's debt to equity ratio has reduced from 49.7% to 47.4% over the past 5 years.
Debt Coverage: APH's debt is well covered by operating cash flow (29.7%).
Interest Coverage: APH's interest payments on its debt are well covered by EBIT (11.5x coverage).
What is Alliance Pharma current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: APH's dividend (1.61%) is higher than the bottom 25% of dividend payers in the UK market (1.37%).
High Dividend: APH's dividend (1.61%) is low compared to the top 25% of dividend payers in the UK market (4.17%).
Stability and Growth of Payments
Stable Dividend: APH's dividend payments have been volatile in the past 10 years.
Growing Dividend: APH's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (48.4%), APH's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: APH's dividends in 3 years are forecast to be well covered by earnings (25.3% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Butterfield (45 yo)
Mr. Peter Jonathan Butterfield has been Chief Executive Officer of Alliance Pharma plc since May 01, 2018. Mr. Butterfield served as Deputy Chief Executive Officer and Chief Operating Officer of Alliance P...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD810.37K) is about average for companies of similar size in the UK market ($USD1.03M).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Experienced Management: APH's management team is seasoned and experienced (5.8 years average tenure).
Experienced Board: APH's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alliance Pharma plc's employee growth, exchange listings and data sources
- Name: Alliance Pharma plc
- Ticker: APH
- Exchange: AIM
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£546.929m
- Shares outstanding: 537.26m
- Website: https://www.alliancepharmaceuticals.com
Number of Employees
- Alliance Pharma plc
- Avonbridge House
- Bath Road
- SN15 2BB
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 21:42|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.